PL EN
REVIEW PAPER
Current diagnostic and therapeutic approaches in obesity management
 
More details
Hide details
1
Research and Development, Maria Skłodowska-Curie Diagnostic Center, Warsaw, Maria Skłodowska-Curie Medical University of Warsaw, Polska
 
These authors had equal contribution to this work
 
 
Corresponding author
Anna Wójcik   

Badania i rozwój, Centrum Diagnostyczne im. Marii Skłodowskiej-Curie, Warszawa,, Uczelnia Medyczna im. Marii Skłodowskiej-Curie Warszawa, Al. "Solidarności" 12, 03-411, Warszawa, Polska
 
 
 
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Obesity is a chronic disease with a complex etiology, and its increasing prevalence constitutes a significant challenge for contemporary healthcare systems. Due to the multifactorial nature of the disease, involving interactions between biological, environmental, and behavioural factors, effective management requires a comprehensive diagnostic and therapeutic approach. The aim of this study is to present current recommendations for the diagnosis and treatment of obesity, with particular emphasis on the role of lifestyle and the patient’s living environment in the context of contemporary therapeutic strategies.

Brief description of the state of knowledge:
Current evidence indicates that the development of obesity results from the interaction of genetic predisposition, neuroendocrine regulation, and environmental and behavioural factors. The contemporary living environment, characterized by high availability of highly processed foods, reduced physical activity, and the predominance of sedentary lifestyle, promotes a positive energy balance. Increasing attention is also being paid to environmental and chemical risk factors, such as endocrine disruptors, air pollution, and characteristics of the school environment, which may modify metabolic processes and increase susceptibility to the development of obesity, particularly during childhood and adolescence.

Summary:
Effective obesity management requires a long-term, individualized approach that incorporates both clinical interventions and preventive measures aimed at the modification of the living environment. Integrating the perspective of environmental medicine with current therapeutic strategies constitutes an important element in reducing the prevalence of obesity and its associated complications.
REFERENCES (41)
1.
Yanovski SZ, Yanovski JA. Approach to obesity treatment in primary care. JAMA Intern Med. 2024;184(7):818–829.
 
2.
World Health Organization. Obesity and overweight. Geneva: WHO; 2023.
 
3.
Traczyk I, Kucharska A, Sińska BI, et al. Prevalence of overweight, obesity, and abdominal obesity in Polish adults. Nutrients. 2024;16(23):4248.
 
4.
World Health Organization. One in eight people are now living with obesity. Geneva: WHO; 2024.
 
5.
Heindel JJ, Blumberg B. Environmental obesogens: mechanisms and controversies. Annu Rev Pharmacol Toxicol. 2019;59:89–106.
 
6.
Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol. 2021;106(3):306–319.
 
7.
Bouchard C. Genetics of obesity: what we have learned over decades of research. Obesity (Silver Spring). 2021;29:802–820.
 
8.
Faccioli N, Poitou C, Clément K, Dubern B. Current treatments for patients with genetic obesity. J Clin Res Pediatr Endocrinol. 2023;15(2):108–119.
 
9.
Aronne LJ, Hall KD, Jakicic JM, et al. Describing the weight-reduced state: physiology, behavior, and interventions. Obesity (Silver Spring). 2021;29(Suppl 1):S9–S24.
 
10.
Gajewska D, Harton A. Current nutritional status of the Polish population – focus on body weight status. J Health Inequalities. 2023;9(2):154–160.
 
11.
World Health Organization. Report of the Commission on Ending Childhood Obesity. Geneva: WHO; 2016.
 
12.
Atlantis E, John JR, Hocking SL, et al. Development and validation of the Edmonton Obesity Staging System-2 (EOSS-2). BMJ Open. 2022;12:e061251.
 
13.
Zalecenia kliniczne dotyczące postępowania u chorych na otyłość 2024. Stanowisko Polskiego Towarzystwa Leczenia Otyłości. Medycyna Praktyczna – Wydanie Specjalne. 2024.
 
14.
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389:514–526.
 
15.
Sanyal AJ, Kaplan LM, Frías JP, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:2037–2048.
 
16.
Lahooti A, Rizvi A, Baig MU, et al. Ten-year outcomes of endoscopic sleeve gastroplasty. Am J Gastroenterol. 2024.
 
17.
GBD 2021 Adolescent BMI Collaborators. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050. Lancet. 2025;405:785–812.
 
18.
Lavie CJ, Laddu D, Arena R, et al. Healthy weight and obesity prevention: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:1506–1531.
 
19.
Roberts S, Pilard L, Chen J, et al. Efficacy of population-wide diabetes and obesity prevention programs. Obes Rev. 2019;20:947–963.
 
20.
Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151:e2022060640.
 
21.
Duan P, Li C, Yuan Z, et al. Multi-component school intervention reduces obesity and improves health behaviors in children. Sci Rep. 2025;15:40607.
 
22.
Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity—assessment, treatment, and prevention. J Clin Endocrinol Metab. 2017;102:709–757.
 
23.
Spiga F, Davies AL, Tomlinson E, et al. Interventions to prevent obesity in children aged 5 to 11 years old. Cochrane Database Syst Rev. 2024;5:CD015328.
 
24.
Mozaffarian D, Afshin A, Benowitz NL, et al. Population approaches to improve diet, physical activity, and smoking habits. Circulation. 2012;126:1514–1563.
 
25.
Buchanan LR, Wethington HR, Finnie RKC, et al. School dietary and physical activity interventions. Am J Prev Med. 2023;64:441–451.
 
26.
Woodruff TJ. Health effects of fossil fuel-derived endocrine disruptors. N Engl J Med. 2024;390:922–933.
 
27.
Lobstein T, Brownell KD. Endocrine-disrupting chemicals and obesity risk. Obes Rev. 2021;22:e13332.
 
28.
Shi X, Zheng Y, Cui H, et al. Exposure to outdoor and indoor air pollution and risk of overweight and obesity. Ecotoxicol Environ Saf. 2022;242:113893.
 
29.
van Rijswijk AS, van Olst N, Schats W, et al. What is weight loss after bariatric surgery expressed as percentage total weight loss? Obes Surg. 2021;31:3833–3847.
 
30.
Busetto L, Dicker D, Frühbeck G, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024;30:2395–2399.
 
31.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.
 
32.
Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes: SELECT trial. Nat Med. 2024;30:2049–2057.
 
33.
Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes. JAMA. 2021;326:2031–2042.
 
34.
Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of tirzepatide (SURPASS-1). Lancet. 2021;398:143–155.
 
35.
Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine (SURPASS-4). Lancet. 2021;398:1811–1824.
 
36.
Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish Obese Subjects Study. N Engl J Med. 2007;357:741–752.
 
37.
Bleich SN, Vercammen KA, Zatz LY, et al. Interventions to prevent global childhood overweight and obesity. Lancet Diabetes Endocrinol. 2018;6:332–346.
 
38.
Jaskulak M, Zimowska M, Rolbiecka M, Zorena K. Environmental obesogens in the obesity epidemic. Ecotoxicol Environ Saf. 2025;299:118401.
 
39.
Heindel JJ, Alvarez JA, Atlas E, et al. Obesogens and obesity: state-of-the-science. Am J Clin Nutr. 2023;118:329–337.
 
40.
U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Silver Spring (MD): FDA; 2026.
 
41.
GBD 2021 US Obesity Forecasting Collaborators. National-level and state-level prevalence of overweight and obesity in the USA. Lancet. 2024;404:2278–2298.
 
eISSN:2084-6312
ISSN:1505-7054
Journals System - logo
Scroll to top